News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Jun 2, 2025, 08:12

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Supports early‐stage (Phase I) development of highly innovative technologies that offer novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology. Projects must focus on creating tools with transformative potential—beyond incremental improvements—to accelerate basic, clinical, or epidemiological cancer research.

Eligibility Criteria

  • Eligible organizations: U.S. and foreign higher education institutions, nonprofits, for‐profit organizations (including small businesses), local/state governments, and other entities listed in Section III.1.

  • PD/PI(s) must have eRA Commons accounts.

  • Projects must be exploratory, technology‐development focused (no clinical trials).

  • Preliminary data are not required but may be included.

  • Applications lacking clear, quantitative performance measures or focused on hypothesis‐driven biological questions (rather than tool development) will be considered nonresponsive.

Funding Details

  • Mechanism: R61 Phase I Exploratory/Developmental Grant

  • Direct costs: Up to $150,000 per year

  • Project period: Up to 3 years

  • Anticipated awards (FY 2026): ~17, totaling $4.2 million

  • No clinical trial costs beyond technology feasibility work

Key Deadlines

  • Letter of Intent: 30 days before application due date

  • Application Due Dates:

    • October 3, 2025 (peer review February 2026; start July 2026)

Biomedical Technology Cancer research cellular analysis early‐stage development exploratory grant Funding opportunity grant application IMAT innovative tools molecular analysis NCI NIH performance measures R61 technology development
Special Coverage
Insight
Jun 13, 2025, 17:21
A New Study by Miguel Varela Rodríguez and Stefanie Plage on AI Visualization in Cancer and Survivorship - Journal of Cancer Survivorship
Insight
Jun 13, 2025, 17:03
Mark Lawler: Great work by Ethna McFerran leading LungSHOT Project on Lung Cancer Screening in Ireland
Blog
Jun 13, 2025, 17:02
Jennifer Douglas: Before I Made a Surgical Decision, I Paused
Science
Jun 13, 2025, 16:45
Benoit Rousseau and Luis Diaz Shared New Findings on MMR Deficient Cancers Published in Cancer Cell by Cell Press
Insight
Jun 13, 2025, 16:39
Eric K. Singhi and Jarushka Naidoo Highlighted Study On Pooled Analysis of Datopotamab Deruxtecan in patients with EGFR–mutated NSCLC
Opinion
Jun 13, 2025, 16:13
BioNTech Acquires CureVac in €1.25B Deal to Expand mRNA Oncology Pipeline
Oncolibrary
Jun 13, 2025, 15:43
New Paper Alert: NRG‑NSABP B‑51/RTOG 1304 Trial on Regional Nodal Irradiation Omission in ypN0 Breast Cancer After Neoadjuvant Chemotherapy
Science
Jun 13, 2025, 15:38
Natalia Baran: Pleased To Share My Latest Review On The Gut-Immune Axis In Primary Immune Thrombocytopenia
Science
Jun 13, 2025, 15:08
Jim Baranski: Can AI Diagnose Lung Cancer?
Science
Jun 13, 2025, 14:09
Marco Donia: CAR-T Cells for Gastro-Oesophageal Cancer - First Randomized Trial of CAR-T in Solid Tumors
Oncolibrary
Jun 13, 2025, 13:39
Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect
Blog
Jun 13, 2025, 13:38
Tsetsegsaikhan Batmunkh: It Was a Pleasure To Meet Assistant Secretary Lucienne Manton from Australia in Mongolia